Treatment outcome data from the different cytogenetic subgroups included in this study, given as 3-year event-free survival rates and 95% confidence intervals
| Cytogenetic subgroup . | n . | pEFS, 3 y, % . | 95% CI . | P, log-rank . |
|---|---|---|---|---|
| All patients | 99 | 52.1 | 41.8–62.4 | |
| t(8;21) | 11 | 54.5 | 25.1–84.0 | .53 |
| Inv(16) | 10 | 66.7 | 35.9–97.5 | .39 |
| Normal karyotype | 26 | 68.4 | 50.2–86.5 | .09 |
| Abnormalities 5/7 | 8 | 50.0 | 15.4–84.6 | .56 |
| t(9;11) | 9 | 55.6 | 23.1–88.0 | .84 |
| Other 11q23 translocations | 8 | 25.0 | 0.0–55.0 | .01 |
| Single random abnormalities | 12 | 27.8 | 0.0–58.8 | .64 |
| Multiple abnormalities | 8 | 62.5 | 29.0–69.0 | .70 |
| Cytogenetic subgroup . | n . | pEFS, 3 y, % . | 95% CI . | P, log-rank . |
|---|---|---|---|---|
| All patients | 99 | 52.1 | 41.8–62.4 | |
| t(8;21) | 11 | 54.5 | 25.1–84.0 | .53 |
| Inv(16) | 10 | 66.7 | 35.9–97.5 | .39 |
| Normal karyotype | 26 | 68.4 | 50.2–86.5 | .09 |
| Abnormalities 5/7 | 8 | 50.0 | 15.4–84.6 | .56 |
| t(9;11) | 9 | 55.6 | 23.1–88.0 | .84 |
| Other 11q23 translocations | 8 | 25.0 | 0.0–55.0 | .01 |
| Single random abnormalities | 12 | 27.8 | 0.0–58.8 | .64 |
| Multiple abnormalities | 8 | 62.5 | 29.0–69.0 | .70 |
The 2 patients with 11q23 translocations without known karyotype and 1 patient in the “normal cytogenetics” subgroup (not treated with curative attempt), as well as the Down syndrome AML patients, were excluded. The subgroups with less than 5 patients were not analyzed for treatment outcome (ie, t(15;17) and trisomy 8).
P, log-rank compares the 3-year probability of event-free survival (pEFS) of that particular cytogenetic subgroup versus the complementary AML group.
n indicates number of patients included in the analysis; CI, confidence interval.